DEVELOPMENT OF POLYMERIC CARRIERS USED FOR BEVACIZUMAB - A POSSIBLE REMEDY IN RETINOPATHY OF PREMATURITY

The aim of this research was to obtain two different polymeric drug delivery systems used for bevacizumab and to analyze the pH of carriers’ solutions and their irritation potential on the mice skin. Bevacizumab, known in medical science as Avastin, is a substance used as angiogenesis inhibitor (a drug which slows the growth of new blood vessels). It was licensed for the treatment of colorectal, lung, breast, kidney, and ovarian cancers, but on the other hand, many researchers have noticed impressive results in the field of severe retinopath y of prematurity. In this research, two different polymeric microstructures were obtained and tested as drug delivery systems: a poly(lactic-co-glycolic) acid carrier and a poly(ether-urethane) carrier; the drug delivery systems’ solutions were characterized by pH, size and Zeta potential, and their irritation potential was studied using a protocol based on the skin mouse model. There were applied carriers’ solutions on C57BL/6 mice skin (topic application) and there were analyzed the changes of skin parameters using non-invasive procedures (tewametry, mexametry). No important changes were reported. According this data, these polymeric microstructures can be used for further applications.